SITC 2018 Abstracts

Biomarkers and Immune Monitoring

Return to Category List

Search word or phrase:   New Search

#TitleAuthorsKeywords
P13Molecular profiling of anti-PD-1 treated melanoma patients reveals importance of assessing neoantigen burden and tumor escape mechanisms for clinical treatmentCharles W. Abbott, III, PhD; Sean M. Boyle, PhD; Eric Levy, PhD; Rena McClory; Sekwon Jang, MD; Richard ChenBioinformatics; Biomarkers; Gene expression; Immune monitoring; Neoantigens; Tumor evasion; Tumor microenvironment
P14Durvalumab treatment-induced transcriptional changes in the tumor microenvironment associated with longer survival in patients with late stage Non-Small Cell Lung Cancer (NSCLC)Ikbel Achour, PhD; Zachary A. Cooper, PhD; Sriram Sridhar; Maria L. Ascierto, PhD; Jixin Wang; Young S. Lee; Natasha Angra; Shaad E. Abdullah, MD, FACP; Rajiv G. Raja, PhD; Brandon W. Higgs, PhD; Maria Jure-Kunkel B cell; Biomarkers; Checkpoint blockade; Dendritic cell; Gene expression; Immune contexture; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
P15Development of a Robust, Simplified Method to Measure Receptor Occupancy in Peripheral Blood from Patients Treated with a Novel Anti-PD-1 Agent, AB122Devika Ashok, PhD; Dana Piovesan, MSc; Sharon Zhao; Hema Singh; Steve W. Young, PhD; Matthew J. Walters, PhD; Lisa Seitz, MSc Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Solid tumors; T cell
P16Better efficacy of PD-1 antibody predicted by immune-related adverse effects is impaired by high dose steroidsXue Bai, MD; Michelle Kim; Gyulnara Kasumova; Tatyana Sharova; Justine V. Cohen, DO; Donald Lawrence, MD; Christine Freedman, RN; Riley Fadden, NP; Krista M. Rubin, MS, FNP-BC; Ryan J. Sullivan, MD; Keith T. Flaherty; Genevieve M. Boland, MD, PhD; Biomarkers; Checkpoint blockade; Clinical study; Immune suppression; Immune toxicity
P17Combined MAGE-A1,3/6,4, and 10 expression levels quantified in solid tumors by (BaseScope™) RNA in situ hybridization (ISH) identify targets for immunotherapyAnshika Bajaj, PhD; Helly Xiao Yan Pimentel; Bingqing Zhang, PhD; Ruby Hsu, PhD; Peter Berglund, PhD; Jan H. Ter Meulen, MD, PhDAdoptive immunotherapy; Biomarkers; Dendritic cell; Gene expression; Solid tumors; Targeted therapy; Tumor antigens; Vaccine
P18Preliminary Evaluation of a Novel Whole Slide Multispectral Assessment of Seven Markers: Potential to Minimize Bias in the Characterization of the Tumor Immune EnvironmentCarmen Ballesteros Merino, PhD; Shawn M. Jensen, PhD; Carla Coltharp, PhD; Kristin Roman, MS; Chichung Wang; Nikhil Lonberg, HSDG; Sebastian Marwitz; Tarsem L. Moudgil, MS; William L. Miller, BS; William L. Redmond, PhD; Yoshinobu Koguchi, MD, PhD; Carlo B. Bifulco, MD; Clifford C. Hoyt, MS; Bernard A. Fox, PhDBiomarkers; Immune contexture; Immune monitoring; Immunoscore; Tumor microenvironment; Tumor stroma
P19Molecular determinants of response to PD-L1 blockade across tumor typesRomain Banchereau; Ning Leng; Edward E. Kadel, III, BS; Dorothee Nickles, PhD; Steve Lianoglou, BS, MSc, PhD; Oliver Zill; Sushit Jhunjhunwala; Luciana Molinero, PhD; Mahrukh Huseni; Marcin Kowanetz, Ph.D.; Richard Bourgon, BS, PhD; Craig Cummings, PhD; Sanjeev Mariathasan, PhD; Priti S. Hegde, PhD; Thomas Powles, MBBS, MD, MRCP Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Systems biology
P20A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imagingLeeat Keren; Marc Bosse; Robert West; Sean C. Bendall, PhD; Michael Angelo, MD, PhD; Bioinformatics; Biomarkers; Checkpoint blockade; Immune tolerance; Proteomics; Systems biology; Tumor microenvironment
P21Deep learning-based PD-L1 tumor cell (TC) scoring improves survival prediction compared to pathologists on durvalumab-treated NSCLC patientsNicolas Brieu, PhD; Ansh Kapil; Aleksandra Zuraw, Dr.; Supporting Author - Abraham Silva, MD; Supporting Author - Marlon C. Rebelatto, DVM, PhD, DACVP; Supporting Author - Keith E. Steele, DVM, PhD; Presenting Author - Guenter Schmidt, PhD; Bioinformatics; Biomarkers; Checkpoint blockade
P22Impact of tumor inherent interferons on immune reactivity and personalized therapy in triple negative breast cancerNatasha K. Brockwell, BBiomed (Hons); Jai Rautela; Tim Molloy, PhD; Sandra O'Toole, MD, PhD; Vinod Ganju, MBBS, FRACP; Belinda S. Parker; Biomarkers; Checkpoint blockade; Chemotherapy; Immune contexture; Immune monitoring; Immunoscore; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment; Tumor stroma
P23Centrifuge-less immunostaining of suspension cells for flow cytometry analysis by DA-Cell™ washer and plate for superior data and workflowNamyong Kim, PhD; Melvin LyeCAR T cells; Immune monitoring; Systems biology; T cell
P24Centrifuge-less red blood cell lysis and immunostaining of whole blood for flow cytometry using DA-Cell washer and plateMelvin Lye; Namyong Kim, PhD B cell; Biomarkers; CAR T cells; Immune monitoring; Immune tolerance; Immune toxicity
P25Consistent pharmacodynamics and immunological responses to the TLR9 agonist, SD-101, following intratumoral injection in multiple cancer typesAlbert F. Candia, PhD; Cristiana Guiducci, PhD; Ezra Cohen, MD; Ronald Levy, MD; Mohammed Milhem, MBBS; Antoni Ribas, MD, PhD; Thomas Tuting, MD; Erick Gamelin, MD PhD; Robert S. Janssen, MD; Robert L. Coffman, Jr., PhD Biomarkers; Checkpoint blockade; Clinical study; Dendritic cell; Gene expression; Immune monitoring; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment
P26High-dimensional flow cytometry of circulating immune cells predicts clinical responses to combination Immune Checkpoint Blockade (ICB) and Radiotherapy (RT) in Gastroesophageal Cancer (GEC)Joseph Chao, MD; Wanqiu Hou; Yi-Jen Chen, MD, PhD; Helen Chen; Michael Tajon; Marwan Fakih, MD; Peter P. Lee, MD; Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Monocyte/Macrophage; Radiotherapy; Solid tumors; T cell
P27Tumor mutational burden assessment on FFPE samples using a targeted next-generation sequencing assayRuchi Chaudhary, PhD; Dinesh Cyanam, PhD; Vinay Mittal; Charles Scafe; Warren Tom, PhD; Janice Au-Young; Seth Sadis; Fiona Hyland Bioinformatics; Biomarkers; Checkpoint blockade
P28Detection and validation of cancer immunotherapy biomarkers in blood and urine-based liquid biopsySimo Zhang; Shidong Jia; Amy Wang; Chen Xie Bioinformatics; Biomarkers
P29Ensemble computational intelligence reveals novel molecular signatures of cancer biology and pan-cancer survivalRichard T. Williams; Thomas Chittenden; Nicholas A. Cilfone, x; Jeffrey R. Gulcher; Bioinformatics; Biomarkers; Systems biology
P30Tracking the cancer immune response using neural network deep learning of serial inflammatory marker data for forecasting timing of therapyBrendon J. Coventry, MD PhD; Mohsen Dorraki, MSc, BS; Anahita Fouladzadeh, BSc; Andrew Alison; Derek Abbott, PhD; Brendon J. Coventry, MD PhD;Bioinformatics; Biomarkers; Immune monitoring; Inflammation; Solid tumors; Systems biology; Targeted therapy
P31Prevalence of high microsatellite instability in cancer patients in the real worldRazvan Cristescu, PhD; Kai-Li Liaw, PhD; Scott Pruitt, MD, PhD; Mark Ayers, PhD; Jianda Yuan, MD, PhD; Thao Vo, MD; Senaka Peter; Andrew Joe, MD PhD; Darcy Hille; Sun Young Rha; Torben Steiniche; Andrey Loboda, PhD Biomarkers
P32Monitoring of M-MDSC vs. G-MDSC in clinical studies – which is more important? (monocytic versus granulocytic myeloid derived suppressor cells)Henry Hepburne-Scott, PhD; Phoebe Bonner-FerrabyAntibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Granulocyte; Immune monitoring; Monocyte/Macrophage; Myeloid cells; MDSC
P33DNA damage detected by localized γH2AX is associated with elevated TILs and PD-L1 expression in human colorectal carcinomas.Shruti Desai, PhD; Parker Sulkowski; Aravind N. Kalathil; Ranjini Sundaram; Ila J. Datar, PHD; Charles Fuchs, MD, MPH; Patricia LoRusso, DO; Ranjit S. Bindra; Kurt A. Schalper, MD, PhDBiomarkers; Checkpoint blockade; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P34Clinical application of urinary cell free DNA as a marker for cancerJeffrey Ding; Debin Sun; Biomarkers; Clinical study; Targeted therapy
P35Development of biomarkers to assess adenosine generation & activity in support of clinical trials conducted with the adenosine receptor antagonist AB928Daniel DiRenzo, PhD; Joanne BL. Tan, PhD; Devika Ashok, PhD; Amy Anderson, PhD; Jenna Jeffrey, PhD; Lisa Seitz, MSc; Manmohan R. Leleti, PhD; Steve W. Young, PhD; Jay P. Powers, PhD; Matthew J. Walters, PhD Biomarkers; Gene expression; Tumor microenvironment
P36Defining the expression of Programmed Death-Ligand 2 in high grade glioma tumor microenvironmentGifty A. Dominah; Victoria E. Sanchez, BS; John Lynes, MD; Nicholas Adamstein; Arnold Obungu, BS, BA; Xiang Wang, MS; Nancy Edwards, BA; Edjah K. Nduom, MD; Antibody; Biomarkers; Checkpoint blockade; Chemotherapy; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor evasion; Tumor microenvironment
P37Multiplexed biomarker quantification to assay and characterize T-cell activationShilan Dong, MS; Jason G. Cahoon, BS; Rachit Ohri, PhD; Shilan Dong, MS; Adoptive immunotherapy; Biomarkers; Costimulation; Cytokine; Immune monitoring; Immune suppression; Proteomics; T cell
P38Highly multiplex spatial immuno-profiling in FFPE tumor tissue with InSituPlex technologySean R. Downing, PhD; Abdul Mohammed, PhD; Abdul Mohammed, PhD; Gourab Chatterjee, PhD; Kevin Hwang, PhD; Julie Xia; Amanda J. Bares, PhD; Michael Murphy; Eloise Wheeler; Armen Changelian; Katir K. Patel, PhD; Bonnie Phillips, PhD; Mael Manesse, PhD Antibody; Biomarkers; Immune contexture; Immune monitoring; Monocyte/Macrophage; Proteomics; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P39PD-L1 expression on tumor versus antigen presenting cells investigated with multiplexed IHC using UltiMapper™ I/O assaysAmy Zhang, M.S.; Amy Zhang, M.S.; Alexis Wong, PhD; Max Rubinstein; Laura Sciarra, PhD; Chakib Boussahmain, Mr., B.S; Bonnie Phillips, PhD; Katir K. Patel, PhD; Sean R. Downing, PhD; Stephanie Hennek, PhD Antibody; Antigen presenting cells; Biomarkers; Immune contexture; Immune monitoring; Immune suppression; Proteomics; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P40Intra-assay and inter-assay assessment of reproducibility and quantification of UltiMapperTM I/O PD-1 and PD-L1 immuno-oncology panels for tissue multiplexingBonnie Phillips, PhD; Bonnie Phillips, PhD; Katir K. Patel, PhD; Courtney Hebert; Jamie Buell; Sean R. Downing, PhDAntibody; Biomarkers; Immune contexture; Immune monitoring; Monocyte/Macrophage; Proteomics; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P41Characterization of circulating biomarkers in subjects with NSCLC using data independent acquisition mass spectrometry reveals host immune response mechanismsNicholas Dupuis, PhD; Jakob Vowinckel, PhD; Daniel Heinzmann; Claudia Escher Biomarkers; Immune monitoring; Inflammation; Proteomics
P42Expanding insights into the colorectal cancer tumor proteome; unbiased protein profiling reveals multiple proteomic-based tumor subtypesJan Muntel; Roland Bruderer; Nicholas Dupuis, PhD; Lukas ReiterBioinformatics; Biomarkers; Gene expression; Proteomics; Solid tumors; Tumor microenvironment
P43The presence of exhausted CD8+ T cells identifies a subset of immunogenic ER+ breast cancer patient tumors Colt Egelston, PhD; Christian Avalos; Diana L. Simons; Min Hui Lim; Peter P. Lee, MDSolid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P44Discovery and screening of protein biomarkers with the FirePlex Technology PlatformTimothy P. Erps; Amy Perea, PhD; Russell Neuner, PhD; Bianca Heinrich, PhD; Wayne Austin; Conor Rafferty, PhD; Matt Camilleri; Long To; James Murray, PhD; Daniel Pregibon, PhD; Elnaz Atabakhsh, PhD Bioinformatics; Biomarkers; Chemokine; Cytokine; Inflammation; Proteomics
P45Tumor infiltrating T cells: complete workflows allow faster and improved analysisCesar Evaristo, PhD; Ramona Siemer, BTA; Philipp Steinbrueck; Zhongjie Yu; David Agorku, BS; Olaf Hardt, PhD; Christian Dose, PhD; Anne Richter, PhDImmune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P47Immune response in patients treated with autologous dendritic cells transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC from the phase I, open label, dose escalation and cohort expansion studyIzak Faiena, MD; Nazy Zomorodian; Beata Berent-Maoz; Ankush Sachadeva; Adrian Bot, MD, PhD; Fairooz Kabinnavar; Jonathan Said; Gardenia Cheung-Lau; Jia Pang; Mignonette Macabali; Tinle Chodon; Xiaoyan Wang; Paula Cabrera; Paula Kaplan-Lezco; Sandy Liu; Begonya Comin-Anduix, PhD; Allan J. Pantuck, MD; Arie Belldegrun, MD, FACS; Karim Chamie, MD; Alexandra Drakaki, MD,PHD; Izak Faiena, MD; Clinical trial; Dendritic cell
P48A high baseline neutrophil-to-lymphocyte ratio in patients receiving anti-PD-1 therapy for head and neck cancer associates with poor prognosis, tumor hypoxia, and tumor M2 macrophage predominanceCorey C. Foster, MD; Riyue Bao, PhD; Sara Kochanny, BA; Arun Khattri, PhD; Rajesh Acharya, MS; Allison Dekker, RN; Yi-Hung Carol Tan, PhD; Elaine Klema, BS; Ryan Brisson, BS; Vassiliki Saloura; Alexander T. Pearson, MD, PhD; Everett E. Vokes, MD; Rom Leidner, MD; Hisham Mehanna, PhD; Tanguy Seiwert, MD Biomarkers; Checkpoint blockade; Gene expression; Immune monitoring; Monocyte/Macrophage; Solid tumors; Tumor microenvironment
P49Comprehensive immune and molecular analysis of a cohort of non-small cell lung cancer (NSCLC) patients treated with a personal neoantigen vaccine, NEO-PV-01, in combination with anti-PD1Joel Greshock; Ramaswamy Govindan, MD; Riley R. Curran; Rana Besada; Samantha J. Gates; Victoria Kohler; Meghan E. Bushway; Julian Scherer, PhD; Ying Sonia Ting; Yuting Huang, Master of Science; Yvonne Ware, Masters; April Lamb; Lisa D. Cleary; Melissa Moles; Joel Greshock; Richard B. Gaynor, MD; Matthew J. Goldstein, MD, PhD; Lakshmi SrinivasanAntigen presenting cells; Biomarkers; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine
P50Characterization of T cell receptor repertoire from FFPE extracted RNA from glioblastoma patients by anchored multiplex PCR and next-generation sequencingLAURA JOHNSON, PhD; Josh D. Haimes; Namitha M. Nair; Angelo Porciuncula, PhD; Kurt A. Schalper, MD, PhD;Immune monitoring; T cell
P51Objective quantitative measurements of PD-L1 expression in tumor tissue by Phosphor Integrated Dots staining in patients with non-small cell lung cancerKazuyuki Hamada, MD, PhD.; Ryotaro Ohkuma, MD; Takehiro Takahashi, MD, PhD.; Takeshi Setogawa; Masaru Takahashi; Hisatake Okada; Hiroo Ishida; Yutaro Kubota, MD, PhD.; Hirotsugu Ariizumi, MD. PhD.; Etsuko Satoh, MD, PhD.; Yuya Hirasawa, MD; Yasutsuna Sasaki, MD, PhD.; Kiyoshi Yoshimura, MD, PhD.; Takuya Tsunoda, MD; Satoshi Wada, MD, PhD.Biomarkers; Checkpoint blockade; T cell; Tumor infiltrating lymphocytes (TILs)
P52Emergence of an ICOShi CD4 T cell subset correlates with tumor reductions in subjects treated with the ICOS agonist antibody JTX-2011Amanda Hanson; Sean M. Lacey, MA Biostatistics; Courtney Hart; Ty McClure; Ellen Hooper, MD; Elizabeth G. Trehu, MD; Deborah Law, DPhil; Christopher Harvey, PhDBiomarkers; Costimulation; Immune monitoring
P53X4P-001, an orally bioavailable CXCR4 antagonist, increases immune cell infiltration and tumor inflammatory status in the microenvironment of melanomaRobert H. Andtbacka, MD, CM, FACS, FRCSC; Robert H. Pierce, Jr., MD; Jean S. Campbell, PhD; Melinda Yushak, MD, MPH; Mohammed Milhem, MBBS; Merrick Ross, MD; Katie Niland; Lu Gan, MD, PhD; Sudha Parasuraman, MD; Yan Wang, PhDAntigen presenting cells; Biomarkers; Checkpoint blockade; Chemokine; Clinical study; Immune suppression; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P54Adenosine signature genes associate with tumor regression in renal cell carcinoma (RCC) patients treated with the adenosine A2A receptor (A2AR) antagonist, CPI-444Andrew Hotson, PhD; Stephen Willingham, PhD; Lawrence Fong, MD; John D. Powderly, II, MD, CPI; Jason J. Luke, MD, FACP; Mario Sznol, MD; Saby George, MD, FACP; Toni K. Choueiri; Marios Giannakis, MD, PhD; Brian I. Rini, MD; Shivaani Kummar, MD; Erik Evensen; Ian McCaffery, PhD; Chunyan Gu; Long Kwei, PhD; Ginna Laport; Joseph J. Buggy; Richard A. Miller, MD; Biomarkers; Clinical trial; Gene expression; Solid tumors; Tumor microenvironment
P55Within the secretome: Immunomodulatory role of extracellular vesicles in breast cancers.Atousa khiabany, Mres; Fabian Flores-Borja, PhD; Ines García Carcedo; Felix Wong; Fabienne Beuron, PhD; Jose vicencio; Andrew Tutt; Tony Ng; SHEEBA IRSHAD, MD PhDImmune tolerance; Inflammation; Tumor evasion; Tumor microenvironment
P56New Dextramer technology for T-cell epitope profiling, and single cell deep phenotyping using DNA barcodes, transcriptomic and genetic sequence analysis, on single cellsKivin KJ. Jacobsen, PhD; Liselotte Brix, phdAdoptive immunotherapy; Antigen presenting cells; Autoimmunity; Bioinformatics; Biomarkers; Carcinogenesis; Immune monitoring; Neoantigens; T cell; Tumor antigens
P57A rapid multi-color fluorescence imaging on frozen tissuesDinesh Jaishankar, PhD; Cormac Cosgrove, PhD; Caroline Le PooleAntibody; Immune monitoring
P58The use of low-coverage sequencing of cell-free DNA for monitoring response to immune checkpoint inhibitors throughout treatmentTaylor J. Jensen, Ph.D.; Aaron M. Goodman; Shumei Kato, MD; Mina Nikanjam; Christopher K. Ellison; Gregory A. Daniels, MD, PhD; Lisa Kim, M.S.; Kimberly Kelly, M.S.; Kerry Fitzgerald, Ph.D.; Erin McCarthy; Prachi Nakashe, M.S.; Amin R. Mazloom; Graham McLennan, M.S.; Daniel S. Grosu, MD, MBA; Mathias Ehrich; Razelle Kurzrock, MDBioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Solid tumors; Systems biology
P59Assessment of consistency of multiplex fluorescent immunohistochemistry data across multiple users utilizing different quantitative analysis strategiesShawn M. Jensen, PhD; Carmen Ballesteros Merino, PhD; Sebastian Marwitz; Nikhil Lonberg, HSDG; Bernard A. Fox, PhDBiomarkers; Immune contexture; Immune monitoring; Immunoscore; Tumor microenvironment
P60Circulating tumor DNA assessment in plasma samples collected in Atezolizumab versus docetaxel in subjects with previously treated non-small-cell lung cancer (OAK) studyYuqiu Jiang, PhD; Namrata S. Patil, Ph.D.; Johnny Wu; Wei Zou; Stephanie Yaung; Aarthi Balasubramanyam; Susan Flynn; Maureen Peterson; Eric Peters; Priti S. Hegde, PhD; Simonetta Mocci; Marcin Kowanetz, Ph.D.; John Palma Bioinformatics; Biomarkers; Checkpoint blockade; Chemotherapy; Solid tumors
P61Development of an exosome / EV analysis pipeline for tumor and immune monitoringJoshua A. Welsh, PhD; Kevin C. Conlon, MD; Milos Miljkovic, MD, MSc; Julia Kepley, BS; Jennifer Marte, BS MD; Jason Savage, PhD; Veronica Galli, PhD; Katherine McKinnon, MS; Katherine Calvo, MD, PhD; Hong Zhang; Cynthia Masison; Fatima Karzai, MD; Fatah Kashanchi; Deborah Citrin; Steve C. Jacobson; James L. Gulley, MD, PhD, FACP; Genoveffa Franchini, PhD; Thomas A. Waldmann, MD; Kevin Camphausen, MD, PhD; Jennifer C. Jones, MD, PhD; Jennifer C. Jones, MD, PhD; Immune contexture; Immune monitoring; Leukemia/Lymphoma; Radiotherapy; Systems biology; Tumor microenvironment
P62A Pan-cancer view of the immune landscape in the tumor microenvironment via RNA and their potential for biomarkers in clinical trialsWendell Jones; B cell; Biomarkers; Gene expression; Monocyte/Macrophage; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P63Estimation of Microsatellite Instability (MSI) by next-generation sequencing using a novel MSI classification method Sameh El-Difrawy; Annie Kraitcheva; Alice Zheng; Simon Crawley; Asha Kamat, PhD;Bioinformatics; Biomarkers; Solid tumors
P64Evaluation of PD-L1 and IRF-1 expression on circulating tumor cells as a predictive biomarker of checkpoint inhibitor responseLaura C. Kennedy, MD PhD; Lance U'Ren, DVM, PhD; Yao Sun; Petros Grivas, MD, PhD; Laura Q. Chow, MD; Vijayakrishna Gadi, MD, PhD; Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring
P65IDO/HLA-DR expression and tumor mutational burden are complementary predictive biomarkers of anti-PD-1 immunotherapy in squamous cell carcinoma of the head and neckArun Khattri, PhD; Ju Young Kim; Riyue Bao, PhD; Rajesh k. Acharya; Yi-Hung Carol Tan, PhD; Rom Leidner, MD; Hisham Mehanna, PhD; Nathan Roscoe; Christine A. Vaupel, PhD; Naveen Dakappagari; Tanguy Seiwert, MD; Sara Kochanny, BA; Antigen presenting cells; Biomarkers; Checkpoint blockade; Immune monitoring; Neoantigens; Tumor infiltrating lymphocytes (TILs)
P66Evaluation of Immune – related Markers in circulating proteome and their association with atezolizumab efficacy in patients with 2L+ NSCLCMarcin Kowanetz, Ph.D.; Ning Leng; Joanna Roder, PhD; Carlos Oliveira, PhD; Senait Asmellash, PhD; Krista Meyer, PhD; Heinrich Roder, DPhil; Marcus Ballinger, PhD; David Shames, Ph.D.; Marcin Kowanetz, Ph.D.; David Shames, Ph.D.; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Immune suppression; Immunoscore; Inflammation; Proteomics; Solid tumors
P67Innovative combinatorial approach to characterize the immune landscape and analyze the tumor response after anti-PD-1 blockade in a 3D ex-vivo tumoroid system of non-small cell lung cancerMelba Marie Page, Ph.D.; Melanie Mediavilla-Varela, PhD; Jenny Kreahling, PhD; Soner Altiok, MD, PhDAntibody; Biomarkers; Checkpoint blockade; Cytokine; Immune monitoring; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P68Using high dimensional mass cytometry (CyTOF) and machine assisted analysis to detect biomarkers in the immunotherapy of cancerCarsten Krieg, PhD; Silvia Guglietta; John M. Wrangle, MD; Luis E. Cardenas, B.S.; Mitchell Levesque; Reinhard Dummer, MD; Burkhard Becher;Mark P. Rubinstein, PhD; Mark Robinson; Carsten Krieg, PhD; Biomarkers; Checkpoint blockade; Clinical trial; Cytokine; Immune monitoring; Inflammation; Monocyte/Macrophage; Myeloid cells; NK/NK T cell
P69Simultaneous quantification of activated immune cells and PD-L1 expressing circulating tumor cells (CTCs) in peripheral blood of cancer patients receiving checkpoint inhibitor therapyRachel Krupa, BS; Robin Richardson; Priscilla Ontiveros; Joseph Schonhoft; Yipeng Wang, PhD, MD; Jiyun Byun, MS; David Lu; Aaron Oh; Sean Nisperos; Mark Landers, MS; Ryan Dittamore, MSBiomarkers; Checkpoint blockade; Immune monitoring; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment
P70CD4+FOXP3+ regulatory T cells in the periphery of HNSCC patients demonstrate high phenotypic diversity depending on Treg subtypeCornelius Kürten, MD; Shanhong Lu; Tullia C. Bruno, PhD; Robert L. Ferris, MD, PhDBiomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; Systems biology; Tumor evasion; Tumor microenvironment
P71Characterization of tumor mutational burden (TMB) and homologous recombination repair (HRR) mutations to assess correlation with immune checkpoint inhibitors (ICIs) response in renal cell carcinomaMatthew K. Labriola, MD; Jason Zhu, MD; Rajan Gupta; Shannon J. McCall, MD; Jennifer JJ. Jackson, PhD; James White, PhD; Elizabeth Weingartner; Eric Kong; Peter Simone, Ph.D.; Eniko Papp, Ph.D.; Kelly Gerding, Ph.D.; Eun-Hae Kim, Ph.D.; John K. Simmons, PhD; Daniel J. George, MD; Tian Zhang, MD; Tian Zhang, MD; Biomarkers; Checkpoint blockade; Solid tumors
P72Biomarker and preliminary pharmacodynamic evaluations of the PD-1 inhibitor ABBV-181 from an ongoing phase 1 clinical trial in patients with advanced solid tumorsStacie L. Lambert; Gregory Vosganian, MD; Fiona Harding, PhD; James Sheridan; Stefan Englert, Dr.; Sara Siggelkow; Apurvasena Parikh, PhD; Betty Wang; Kinjal Hew; Jaishree Bankoti; Marcia Stickler; Eileen Lee; Merriam Mcclellan; Daniel Afar, PhD; Anita Reddy, PhD; Stacie L. Lambert;Biomarkers; Checkpoint blockade; Clinical trial; Solid tumors; T cell
P73Analysis of survival and mRNA expressivity in the tumor microenvironment of adenocarcinoma via K-means clustering algorithmSeongwon Lee, PhD; Andrew Baird, MD; Jillian Dolan, BS; Stuart Baird; Fateeha Furqan, MD; Shinyoung Park, MS; Sunyoung S. Lee, MD, PhD;Gene expression; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P74Validation the immune contexture as prognostic biomarkers in high-grade serous ovarian cancerShin Wha Lee, MD; Ju-hyun Kim; Soo-Jung Kim; Yong-Man KimImmune contexture; Immunoscore
P75Development of a next-generation sequencing-based microsatellite instability assay (MSI-NGS) for solid tumor testingSean T. Glenn, PhD; Sarabjot Pabla, MSc, PhD, BS; Jonathan Andreas, MS; Blake Burgher, BS, RN; Jacob Hagen; Jeffrey Conroy, BS; Mary Nesline, MS; Antonios Papanicolau-Sengos, MD; Vincent Giamo, BS, MS; Felicia L. Lenzo; Maochun Qin, MD, MS; Yirong Wang, M.S.; Mark Gardner; Carl D. Morrison, MD, DVMBiomarkers; Solid tumors
P76Analysis of the complex immune-cell milieu of tumors from patients treated with immunotherapy to better understand clinical responseShumei Kato, MD; Ryosuke Okamura; Mina Nikanjam; Ramez N. Eskander, MD; Paul Fanta, MD; Suzanna Lee; Sean T. Glenn, PhD; Devin Dressman, PhD; Sarabjot Pabla, MSc, PhD, BS; Jeffrey Conroy, BS; Mary Nesline, MS; Antonios Papanicolau-Sengos, MD; Felicia L. Lenzo; Mark Gardner; Carl D. Morrison, MD, DVM; Razelle Kurzrock, MDBiomarkers; Gene expression; Solid tumors; T cell; Tumor microenvironment
P77Identifying major immune-related subsets of GI tumors for clinical purposesAmy P. Early, MD; Sarabjot Pabla, MSc, PhD, BS; Jeffrey Conroy, BS; Mary Nesline, MS; Sean T. Glenn, PhD; Felicia L. Lenzo; Antonios Papanicolau-Sengos, MD; Blake Burgher, BS, RN; Vincent Giamo, BS, MS; Jonathan Andreas, MS; Yirong Wang, M.S.; Carl D. Morrison, MD, DVM Biomarkers; Immune monitoring; Solid tumors; Tumor microenvironment
P78More sensitive identification of T-cell receptor beta rearrangements with an augmented transcriptome methodSean M. Boyle, PhD; Eric Levy, PhD; Gabor Bartha; Pamela Milani; Robin Li; Shujun Luo; Rena McClory; John S. West, MBA; Richard ChenBioinformatics; Biomarkers; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P79Change in neutrophil to lymphocyte ratio during treatment with immune checkpoint inhibitors predicts survival in patients with advanced cancerDan Spakowicz, PhD, MS; Jarred Burkart; Sandip Patel; Marium Husain, MD, MPH; Kai He, MD, PhD; Carolyn Presley; Erin Bertino; Peter Shields; David P. Carbone, MD, PhD; Claire Verschraegen, MD; Greg Otterson; Kari Kendra; Mingjia Li, MD; Dwight Owen Biomarkers; Checkpoint blockade; Immune monitoring; Inflammation
P80Day-to-day profiling of T cell activation by measuring cellular markers and secreted cytokines in a rapid multiplexed cell/bead mixture assayZhaoping Liu, Ph.D.; Adoptive immunotherapy; Biomarkers; CAR T cells; Checkpoint blockade; Cytokine; Immune monitoring; Immune suppression; Immune tolerance; T cell; Tumor evasion
P81Germline encoded TRBV polymorphism predicts adverse events during checkpoint blockade immunotherapyTimothy Looney, PhD; Geoffrey M. Lowman, PhD; Asha Kamat, PhD; Fiona Hyland Autoimmunity; Bioinformatics; Biomarkers; Checkpoint blockade; Genetic polymorphism; Immune monitoring; Immune toxicity; T cell
P82Peripheral blood TCRB repertoire convergence and clonal expansion predict response to anti-CTLA-4 monotherapy for cancerTimothy Looney, PhD; Li Zhang, MD PhD; David Y. Oh, MD, PhD; Denise S. Topacio-Hall, BS, MA; Lawrence Fong, MDBioinformatics; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; T cell; T cell lineages; Tumor antigens
P83T cell receptor beta immune repertoire sequencing in several FFPE tissue types – Interrogation of the tumor microenvironment in archived tissue samplesDenise S. Topacio-Hall, BS, MA; Lauren Miller, BS; Elizabeth Linch, BS; Alice Zheng, PhD; Geoffrey M. Lowman, PhD; Timothy Looney, PhD; Mark Andersen, PhD Biomarkers; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P84Quantitative evaluation of tumor-infiltrating lymphocyte subsets and PD-L1 expression in lung cancer brain metastasesBenjamin Y. Lu, MD; Richa Gupta; Hailey Wyatt; Matthew Ribeiro; Tyler Stewart; Veronica Chiang, MD; Joseph Contessa; Adebowale Adeniran; Harriet Kluger, MD; Lucia Jilaveanu, MD; Kurt A. Schalper, MD, PhD; Sarah B. Goldberg, MD, MPH Immune monitoring; Immune suppression; Inflammation; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma
P85Correlation of clinical response and pathologic treatment effect after 4 weeks of preoperative PD-1 blockade in primary head and neck squamous cell carcinoma (HNSCC)Adam Luginbuhl, MD; Jennifer Johnson, MD; Madalina Tuluc, MD; Stacey Mardekian, MD; Chandala Chitguppi, MD; Larry Harshyne, PhD; Ralph G. Zinner, MD; Joseph Curry, MD; David Cognetti, MD; Ulrich Rodeck, MD PhD; Athanassios Argiris, MD PhDCheckpoint blockade; Clinical trial; Immune monitoring; Immunoscore; Solid tumors; Surgery; Tumor microenvironment
P86T-cell receptor (TCR) repertoire features associated with disease-free survival following infusion with marrow-infiltrating lymphocytes (MILs)Eric R. Lutz, PhD; Alex Hopkins, PhD; LAKSHMI RUDRARAJU, MS; Elizabeth DeOlivera; Ido Weiss, PhD; Rachel Gittelman, PhD; Erik Yusko, PhD; Kathryn G. Boland, DVM, PhD; Ivan M. Borrello, MD; Kimberly A. Noonan, Ph.D.; Adoptive immunotherapy; Biomarkers; Immune monitoring
P87Preliminary evidence of intratumoral activation and immunomodulatory effect of CX-072, a Probody therapeutic antibody prodrug targeting PD-L1, in a phase 1/2a trialSusan K. Lyman; Judi Gordon; Amy DuPage; Preeti Pramanik; Bruce Howng; Michael B. Winter; Irina K. Popova; Olga Vasiljeva; James Jones; Kenneth R. Wong, MA; Victoria Singson; Jennifer H. Richardson, PhD; Beiyao Zheng, PhD; Mark Stroh, PhD; Lori Carman, RN; Vanessa Huels; Karen Autio, MS, MD; Valentina Boni; Daniel C. Cho, MD; Javier Garcia-Corbacho; Iván Victoria Ruiz; Omid Hamid, MD; Nataliya Uboha; Elisabeth de Vries; Anthony El-Khoueiry, MD; Alexander I. Spira, MD, PhD, FACP; Rachel E. Sanborn, MD; Fiona Thistlethwaite, MD, PhD; Hendrik-Tobias Arkenau; Johanna Bendell; Patrick A. Ott, MD, PhD; Naiyer A. Rizvi, MD; Matthias Will, MD; W. Michael Kavanaugh, MD; Aung Naing, MD, FACP; Luc R. R. Desnoyers, Ph. D.Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Gene expression; Immune monitoring; Leukemia/Lymphoma; Solid tumors; T cell; Targeted therapy; Tumor microenvironment
P88Quantitative assessment and standardization of the programmed death 1 ligand 1 (PD-L1) immunohistochemistry companion diagnostic assaysSandra Martinez-Morilla, PhD; John McGuire; Patricia Gaule, PhD; Lauren Moore; Balazs Acs; Delphine Cougot; David L. Rimm, MD, PhD; Antibody; Biomarkers; Checkpoint blockade; Targeted therapy
P90Using artificial intelligence to predict response to immunotherapyJoseph S. Krueger, BS PhD; Karen Ryall, PhD, BS; Navi Mehra; Jenifer Caldara, BS; Will Paces, BS; Kelsey Weigel, PhDBiomarkers; Checkpoint blockade; Clinical trial; Immune contexture; Immune suppression; Immune tolerance; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P91It’s pan-o’clock: Tumor and circulating lymphocytic pan-pathology targets of the failed immune responseAnne Monette, PhD; Antigoni Morou, PhD; Nadia Al-banna; Louise Rousseau, RT; Jean-Baptiste Lattouf, MD, FRCSC; Sara Rahmati; Tomas Tokar; Daniel Kaufmann, MD; Jean-pierre Routy; Igor Jurisica, PhD; Rejean Lapointe, PhDB cell; Bioinformatics; Biomarkers; Gene expression; Immune monitoring; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P92Predictive plasma proteomic biomarkers of immunotherapy toxicity in patients (pts) with metastatic melanoma (MM)Meghan J. Mooradian, MD; Xuesong Gu; Donald Lawrence, MD; Justine V. Cohen, DO; Tatyana Sharova; Genevieve M. Boland, MD, PhD; Towia A. Libermann; Ryan J. Sullivan, MD; Biomarkers; Immune monitoring; Immune toxicity; Proteomics; Solid tumors
P93Pre-analytical variables affect myeloid-derived suppressor cell quantitation by flow cytometryChihiro Morishima, MD; Amy E. Wright; Angela M. Riggins; Chihiro Morishima, MD; Minjun ApodacaBiomarkers; Immune monitoring; Myeloid cells; MDSC
P94Measurement of adenosine and other immunomodulators in the tumor microenvironment by in vivo microdialysisNadege Morisot, PhD; Julien Roeser, PhD; Holden Janssens, PhD; Arash Rassoulpour, PhD Biomarkers; Immune contexture; Immune monitoring; Solid tumors; Tumor microenvironment
P95Modulation of adenosine levels in the tumor microenvironment following treatment with anti-PD1 antibodies and oxaliplatin: an in vivo microdialysis studyArash Rassoulpour, PhD; Nadege Morisot, PhD; Julien Roeser, PhD; Holden Janssens, PhD Antibody; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; Solid tumors; Targeted therapy; Tumor microenvironment
P96Assessment of RNA turbulence and PD-L1 expression on tumor-infiltrating lymphocytes in breast cancerApoorva L. Mylavarapu, BS; Scott Morris; Maulik Patel, PharmD, PhD; Sandip P. Patel, MD Biomarkers; Gene expression; Tumor infiltrating lymphocytes (TILs)
P97Different functionality of CD8 PD-1-positive CD28-negative T cells in the periphery and in the tumor of lung cancer patientsBelinda Palermo; Ornella Franzese; Mariangela Panetta; Giulia Campo; Fabiana Cecere; Virginia Ferraresi; Gabriele Alessandrini; Francesco Facciolo; Gennaro Ciliberto, MD; Paola Nistico', MDCheckpoint blockade; Coinhibition; Costimulation; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
P98High gene expression of estrogen and progesterone receptor is associated with increased T cell infiltration in patients with NSCLCMichael S. Oh, MD; Jonathan Anker, MD; Young Kwang Chae, MD; Gene expression; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P99RRx-001 is a Phase 3-Ready small molecule dual inhibitor of CD47 and SIRPalphaPedro Cabrales, PhD; Bryan Oronsky, MD PhD; Tony Reid, MD PhD; Corey A. Carter, MD; Biomarkers; Checkpoint blockade; Cytokine; Immune monitoring; Immune suppression; Monocyte/Macrophage; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion
P100Exploring dissociated human tissues as an alternative to fresh tissue for multiple downstream applicationsShawn Fahl, Ph.D.; B cell; Biomarkers; Myeloid cells; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P101Evaluation of ctDNA mutations detected in plasma as potential correlate of immunotherapy efficacy in NSCLC patientsNamrata S. Patil, Ph.D.; Yuqiu Jiang, PhD; Wei Zou; Johnny Wu; Stephanie Yaung; Susan Flynn; Maureen Peterson; Eric Peters; Priti S. Hegde, PhD; Marcin Kowanetz, Ph.D.; John Palma; Namrata S. Patil, Ph.D.; David Shames, Ph.D.; Yuqiu Jiang, PhD; Namrata S. Patil, Ph.D.; Biomarkers; Clinical trial; Neoantigens
P102Localized measurement and clinical significance of OX40 and OX40L expression in human non-small cell lung cancer (NSCLC)Angelo Porciuncula, PhD; Micaela Morgado; Sima Zacharek, PhD; Maria Toki, MD, MSc; Kostas Syrigos; Vamsidhar Velcheti, MD FACP; Joshua Frederick, PhD; Roy S. Herbst, MD, PhD; Kurt A. Schalper, MD, PhD Costimulation; Gene expression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P103Bulk and single-cell TCR and transcriptome profiling reveals significant phenotypic, spatial and temporal heterogeneity in the TIL repertoire of pancreatic cancer and melanoma patientsChin Leng Tan; Ignacio Heras-Murillo, MSc.; Katharina Lindner; Aaron Rodriguez Ehrenfried; Lena Appel; Anna-Katharina Koenig; Markus Buechler; Ugur Sahin, MD; Jessica Hassel; Oliver Strobel; Michael Flossdorf; Rienk Offringa, PhD; Isabel Poschke, PhDAdoptive immunotherapy; Immune contexture; Immune monitoring; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P104Radiomic features that can predict response to PD-1 inhibitors in late-stage Non-Small Cell Lung Cancer are also associated with tissue-derived measures of immune responsePrateek Prasanna, PhD; Mohammadhadi Khorrami, PhD; Pradnya Patil; Kaustav Bera, MBBS; Vamsidhar Velcheti, MD FACP; Anant Madabhushi, PhD; Biomarkers; Immune monitoring; Tumor infiltrating lymphocytes (TILs)
P105Response to immunotherapy in hepatocellular carcinoma, a single-institutional analysisPetra Prins; Bhavana P. Singh, MD; AIwu He Biomarkers; Chemotherapy; Solid tumors; Targeted therapy
P106Multiplexed ion beam imaging (MIBI) for characterization of the tumor microenvironment (TME) across tumor types Jason Ptacek, PhD; Rachel Finck; Murat Aksoy; Jay Tarolli; Jessica Finn;Biomarkers; Immune monitoring; Immune suppression; Monocyte/Macrophage; Proteomics; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment
P107A comparative study of the PD-L1 IHC 22C3 and 28-8 assays in melanoma samplesGabriel S. Krigsfeld, Ph.D.; Kim Zerba; James Novotny Jr; Shuntae Williams; Michael Matthews, M.S.; Hytham Al-Masri, PhD; David Gold; James White Antibody; Biomarkers; Checkpoint blockade; Solid tumors
P108HLA class I subtypes are associated with immune-related adverse events in patients with melanoma treated with ipilimumabAnton Safanov; John Pluta; Lu Qian; Ravi Amaravadi; Allison Applegate; Elizabeth Buchbinder, MD; Justine V. Cohen, DO; Claire Friedman, MD; Ruth Halaban, PhD; F. Stephen Hodi, Jr., MD; Christine E. Horak, PhD; Douglas B. Johnson, MD, MSCI; John M. Kirkwood, MD; Tara C. Mitchell; William A. Robinson, MD, PhD; Lynn M. Schuchter, MD; Jeffrey A. Sosman, MD; Mario Sznol, MD; Megan Wind-Rotolo, PhD; Jedd D. Wolchok, MD, PhD; Mingyao Li; Peter Kanetsky; Katherine L. NathansonAntigen presenting cells; Autoimmunity; Bioinformatics; Biomarkers; Checkpoint blockade; Genetic polymorphism; Immune toxicity; Tumor microenvironment
P109Clinical efficacy of immune checkpoint inhibitors in patients with small cell lung cancer is associated with high tumor mutational burden and development of immune-related adverse eventsBiagio Ricciuti, MD; Suzanne Dahlberg; Sasha Kravets; Safiya Subegdjo; Renato Umeton; Adem Albayrak, M.S.; Lynette M. Sholl; Mark M. AwadBiomarkers; Checkpoint blockade; Immune toxicity
P110Modular repertoire analysis of blood transcriptomic immune response in metastatic renal cell carcinoma patients treated with PazopanibDarawan Rinchai, PhD; Elena Verzoni; Agata Cova; Paola Squarcina; Loris D. Cecco; Paolo Grassi; Raffaele Ratta; Veronica Huber; Matteo Dugo; Monica Rodolfo; Jessica Roelands, Master; Damien Chaussabel; Giuseppe Procopio; Davide Bedognetti, MD, PhD; Licia Rivoltini, MD; Bioinformatics; Clinical study; Gene expression; Immune monitoring; Immune suppression; Systems biology
P111Streamlined human immune monitoring with mass cytometry: 29 markers in a single tube with automated data analysisChristina Loh, PhD; Thiru Selvanantham, PhD; Leslie Fung; Michelle M. Poulin; C. Bruce Bagwell; Margaret Inokuma; Clare Rogers, MS; Greg Stelzer, PhD; Steven Lott, PhDB cell; Bioinformatics; Biomarkers; CAR T cells; Immune monitoring; Leukemia/Lymphoma; Monocyte/Macrophage; Myeloid cells; Proteomics; T cell
P112Proteomic profiling of biomarkers for response to checkpoint immunotherapy in melanoma patientsMarijana Rucevic, PhD; Biomarkers; Checkpoint blockade; Immune monitoring; Proteomics
P113Digital spatial profiling of bone-marrow infiltrating immune cells in acute myeloid leukemia. Sergio Rutella, MD, PhD, FRCPath; Jayakumar Vadakekolathu, PhD; Sarah E. Church; Heidi Altmann; Elena Viboch, MS; Jorn Meinel, MD; Yan Liang, MD PhD; Joseph M. Beechem, PhD; Alessandra Cesano, MD, PhD; Sarah Warren, PhD; Gerhard Enhinger, MD; Marc Schmitz, MD; Martin Bornhauser, MD; Sergio Rutella, MD, PhD, FRCPath;Gene expression; Immune contexture; Immune suppression; Immune tolerance; Leukemia/Lymphoma; Monocyte/Macrophage; Tumor evasion; Tumor microenvironment
P114ImmunoINTEL, a flow cytometry based platform that identifies and quantifies the most critical cell subsets and related functional potential in dissociated solid tumorsKonstantin Salojin, PhD; Christine Hauther; Dai Liu; Santosh Putta; Norman B. Purvis, Jr., PhD; Matt Westfall, PhDBiomarkers; Immune monitoring; Immunoscore; Monocyte/Macrophage; MDSC; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P115Predictive and pharmacodynamic biomarkers associated with treatment with the oral selective AXL Inhibitor bemcentinib in combination with pembrolizumab in patients with advanced NSCLC and MelanomaRobert Holt, PhD; David Micklem, PhD; Anthony Brown; Cornelia Schuster; Oddbjørn Straume; James Lorens, PhDBiomarkers; Checkpoint blockade; Chemokine; Clinical study; Clinical trial; Coinhibition; Cytokine; Targeted therapy
P116Quantitative measurement of CD8, CD68 and PD-L1 expression in a novel multiplex assay and associations of overall survival in non-small cell lung cancer (NSCLC) patients treated with anti-PD-1 TherapyFahad S. Shabbir, MD; Jon Zugazagoitia, MD; Yuting Liu, PhD candidate; Katir K. Patel, PhD; Brian S. Henick, MD; Scott N. Gettinger, MD; Roy S. Herbst, MD, PhD; Kurt A. Schalper, MD, PhD; David L. Rimm, MD, PhDAntibody; Biomarkers; Checkpoint blockade; Immune monitoring; Monocyte/Macrophage; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P117Host immune response in undifferentiated pleomorphic sarcoma – 10-year retrospective analysisJoseph Sheridan; Andrew Horvai; Ross Okimoto; Rosanna Wustrack; Immune monitoring; Solid tumors; Surgery; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P118Immunosuppression involving MDSC and IL-17 is associated with decreased levels of serum rapid turnover protein and shorter survival in patients with gastrointestinal cancerMasahiko Shibata, MD; Kenji Gonda, MD, PhD; Takahiro Nakajima; Tatsuo Shimura; Koji Kono; Seiichi Takenoshita; Biomarkers; Cytokine; Immune suppression; Immune tolerance; Inflammation; Myeloid cells; MDSC
P119Fab-selective proteolysis coupled with liquid chromatography-mass spectrometry for monitoring therapeutic antibodies in circulationTAKASHI SHIMADA, PhD; Noriko Iwamoto, PhDAntibody; Biomarkers; Immune monitoring
P120Validated next generation sequencing assay for the characterization of the T-cell repertoire from RNAJennifer K. Sims; Martin Buchkovich, PhD; Jason Powers; Victor J. Weigman, Jr.; John Pufky; Jennifer Mason, PhD; Patrick Hurban, PhDBiomarkers; Immune monitoring; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P121Interaction of immune checkpoints in tumor-stromal microenvironment of primary and chemoreduced retinoblastomaLata Singh, Ph.D.; Mithalesh K. Singh; Seema Kashyap; Seema Sen, MD; Moshahid A. Rizvi, PhD; Chemotherapy; Pediatric tumors; Tumor microenvironment; Tumor stroma
P122Validated next generation sequencing RNA-based assay of the IGHV mutation status and repertoire diversityJeran Stratford; Jennifer K. Sims; Patrick Hurban, PhD; Victor J. Weigman, Jr.; Antibody; B cell; Bioinformatics; Biomarkers; Immune monitoring
P123Peripheral blood lymphocyte responses in patients with renal cell carcinoma treated with high-dose interleukin-2Rupal Bhatt, MD, PhD; Lei Sun, Ph.D; William J. Slichenmyer, MD; Sean Rossi; Juan C. Alvarez, PhD; Wenxin Xu, MD; Heather C. Losey, PhDBiomarkers; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell
P124Quantitative multichannel immunofluorescence imaging to assess the immune composition of the T cell-inflamed tumor microenvironment in bladder cancerRandy F. Sweis, MD; Ken Hatogai; Danny Kim; Yuanyuan Zha, PhD; Alexander T. Pearson, MD, PhD; Gary D. Steinberg, MD; Thomas F. Gajewski, MD, PhD; Antigen presenting cells; Biomarkers; Checkpoint blockade; Dendritic cell; Immune contexture; Immune monitoring; Inflammation; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P125DNA methylation biomarkers for noninvassive detection of hepatocellular carcinomaDavid J. Taggart, PhD; Dhruvajyoti Roy, PhD; Gen Li; Dan Liu; Lianghong Zheng; Kang Zhang; Biomarkers; Clinical study; Solid tumors
P126Peripheral immune monitoring identifies biomarkers of response and toxicity after neoadjuvant combination immunotherapy with ipilimumab (ipi) and high dose IFNα2b (HDI) in patients with melanomaAhmad A. Tarhini, MD, PhD; Ghanashyam Sarikonda; Arjun Khunger, MD; Jack El-Sawada, MD; Christian Laing; Christine A. Vaupel, PhD; Naveen DakappagariBiomarkers; Checkpoint blockade; Clinical study; Clinical trial; Cytokine; Immune monitoring; MDSC; Regulatory T cell (Treg cell); Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P127Characterization of changes in tumor immune microenvironment after treatment with neoadjuvant combination immunotherapy with ipilimumab (ipi) and high dose IFNα2b (HDI) in patients with melanomaArjun Khunger, MD; Jennifer Bordeaux, PhD; Ju Young Kim; Christine A. Vaupel, PhD; Naveen Dakappagari; Ahmad A. Tarhini, MD, PhDBiomarkers; Checkpoint blockade; Immune monitoring; MDSC; Regulatory T cell (Treg cell); Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P128Multiplexed immunofluorescent assay development for study of the PD-1/PD-L1 checkpoint in the tumor immune microenvironment (TIME)Sneha Berry, MS; Nicolas A. Giraldo, MD PhD; Peter Nguyen, MS; Benjamin Green, BS; Haiying Xu; Aleksandra Ogurtsova; Abha Soni, DO; Farah Succaria, MD; Daphne Wang, MS; Charles Roberts; Julie E. Stein, MD; Elizabeth L. Engle, MSc; Drew M. Pardoll, MD, PhD; Robert A. Anders, MD, PhD; Tricia Cottrell, MD, PhD; Janis M. Taube, MD, MSCBiomarkers; Checkpoint blockade; Solid tumors; Tumor microenvironment
P129Simultaneous single cell analysis of multiple analytes resolves T cell populations at high resolutionSarah Taylor, PhD; Katherine A. Pfeiffer; Michael JT. Stubbington, PhD; Josephine Y. Lee; Jerald Sapida; Liselotte Brix, phd; Kivin KJ. Jacobsen, PhD; Bertrand Yeung; Xinfang Zhao; Tarjei Mikkelsen; Deanna M. Church, PhDAntigen presenting cells; Gene expression; Immune monitoring; Neoantigens; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment
P130A measurable immune response in the tumors and lymph nodes of patients with lymph node positive and lymph node negative breast cancer.Archana Thakur, PhD; Dana L. Schalk; Tayson Lin; Griffin R. Calme, B.S.; Johnson Ung; Lawrence G. Lum, MD, DSc; Lydia ChoiBiomarkers; Immunoscore; T cell; Tumor infiltrating lymphocytes (TILs)
P131High-plex predictive marker discovery for melanoma immunotherapy treated patients using NanoString® Digital Spatial ProfilingMaria Toki, MD, MSc; Pok Fai Wong, MD, MPhil; James W. Smithy, MD, MHS; Harriet Kluger, MD; Chris Merritt, PhD; Giang Ong, MS; Sarah Warren, PhD; Joseph M. Beechem, PhD; David L. Rimm, MD, PhDBiomarkers; Checkpoint blockade; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P132RNA sequencing of rare antigen-specific T cells and tissue micro-regions using the RareCyte platformLance U'Ren, DVM, PhD; Rebecca Podyminogin; Nolan Ericson; Eric Kaldjian, MD; Tad George, PhDBiomarkers; Immune contexture; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma
P133Spatially resolved and multiplexed immunoprofiling of NSCLC using imaging mass cytometry reveals distinct functional profile of CD4 and CD8 TILs associated with response to immune checkpoint blockersFranz Villarroel-Espindola, Ph.D.; Miguel F. Sanmamed, MD, PhD; Jonathan Patsenker; Ya-Wei Lin; Brian S. Henick, MD; Jovian Yu; Mark Verburg; Tayf Badri; Jon Zugazagoitia, MD; Daniel E. Carvajal-Hausdorf, MD; Ruth Montgomery, Ph.D.; Roy S. Herbst, MD, PhD; Lieping Chen, MD, PhD; David L. Rimm, MD, PhD; Tal Shnitzer, Ph.D.; Ronen Talmon, Ph.D.; Yuval Kluger, Ph.D.; Kurt A. Schalper, MD, PhD; Antibody; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P134Prognostic and predictive value of baseline biomarkers in advanced non-small cell lung cancer (NSCLC)Huifen Wang, PhD; Robert McEwen; Ketan Patel, PhD; Binbing Yu; J Carl Barrett; Kris Sachsenmeier, PhDAdoptive immunotherapy; Biomarkers
P135Integrative genomic and proteomic analysis identifies cancer subtypes and signaling networks associated with aberrant tumor expression of VISTADuncan Whitney, PhD; Anna W. Ma, MS; Ramachandra Mu. Katabathula, Ph.D.; Timothy Wyant; Jefferson Parker; Salendra Singh, MS; David Tuck; Vinay Varadan, PhD;Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; Tumor stroma
P136Genetic immunosignatures associate with progression-free survival in advanced soft tissue sarcoma patients treated on a Phase 2 trial of the VEGF receptor inhibitor axitinib plus pembrolizumabBreelyn A. Wilky, MD; SuFey Ong; Sarah Warren, PhD; Alessandra Cesano, MD, PhD; Despina Kolonias; Eric Wieder, PhD; Deukwoo Kwon, PhD; Andrew Rosenberg, MD; Jonathan C. Trent, MD, PhD; Krishna Komanduri, MDAngiogenesis; Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Solid tumors
P137A systematic literature review (SLR) of tumor mutational burden (TMB) and efficacy with immunotherapy (IO) in lung cancerConnor Willis, PharmD; Michelle Fiander; Dao Tran, PharmD; Beata Korytowsky; John-michael Thomas, PharmD; Signe Fransen; Florencio Calderon; Teresa Zyczynski; Lisa Siegartel; Diana Brixner; David Stenehjem; Connor Willis, PharmD; Biomarkers; Checkpoint blockade; Solid tumors
P138Quantitative assessment of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanomaPok Fai Wong, MD, MPhil; Wei Wei, MD, PhD; Swati Gupta, PhD; James W. Smithy, MD, MHS; Harriet Kluger, MD; David L. Rimm, MD, PhDBiomarkers; Checkpoint blockade; Clinical study; Solid tumors; Tumor microenvironment; Tumor stroma
P139Pharmacodynamic effects of CA170, a first-in-class small molecule oral immune checkpoint inhibitor (ICI) dually targeting V-domain Ig suppressor of T-cell activation (VISTA) and PD-L1Timothy L. Wyant, PhD; Hongwei Wang, MD, PhD; David Tuck; Yung-Jue Bang, MD PhD; Anna W. Ma, MS; Jeffrey A. Sosman, MD; Adil Daud, MBBS MD; John D. Powderly, II, MD, CPI; Javier Garcia-Corbacho; Manish R. Patel, MD; James J. Lee, MD, PhD; Kyu-Pyo Kim; Joshua Brody, MD; Sun Young Rha; Erika P. Hamilton, MD; Marta Gil Martin; Santiago Ponce Aix, MD; Radhakrishnan Ramchandren, MD; Myung-Ju Ahn; James Spicer, MD, PhD; Simon Pacey; Gerald S. Falchook, MD; Funda Meric-Bernstam, MDBiomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs)
P140Deep profiling of Asian NSCLC to identify the tumor antigen-specific T cells and the predictive potential of the patients treated with PD-1/PD-L1 blockadeJoe P. Yeong, MBBS, PhD; Lisda Suteja; Yannick Simoni; Kah Weng Lau; Sherlly Lim; Jie Hua, Josh Loh; Angela Takano; Eng Huat Tan, MD; Kiat Hon, Tony Lim; S. W., Daniel Tan; Evan W. Newell, PhD; Adoptive immunotherapy; Biomarkers; Checkpoint blockade; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment
P141Circulating tumor DNA ( ctDNA) a novel biomarker for immunotherapy response in advanced lung cancerEbenezer O. Appah, MD; Katherine B. Neblett; Clive D. Morris; Greg Jones; Vincent Plagnol; Paul R. Walker, MD; Meera Yogarajah, MDCheckpoint blockade; Immune monitoring
P142The immunogenomic impact of indoximod on the tumor microenvironment of melanoma patientsJiayi Yu, PhD; Gabriela R. Rossi, PhD; Ravindra Kohle, MD, PhD; David H. Munn, MD; Yousef Zakharia, MD; Nicholas Vahanian, MD; Eugene P. Kennedy, MD, FACS; Charles Link, Jr., MDBiomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Solid tumors; Tumor microenvironment
P143Rational combination of GITR agonism with PD-1 blockade in cancer patientsRoberta Zappasodi, PhD; Cynthia Sirard, MD; Yanyun Li, PhD MD; Sadna Budhu, PhD; Moshen Abu-Akeel; Cailian Liu, MD; Xia Yang; Hong Zhong, BS; Walter Newman, PhD; Jingjing Qi; Phillip Wong, PhD; David Schaer; Henry Koon, MD; Vamsidhar Velcheti, MD FACP; Michael Postow, MD; Margaret K. Callahan, MD, PhD; Jedd D. Wolchok, MD, PhD; Taha Merghoub, PhD; Biomarkers; Checkpoint blockade; Costimulation; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion
P144A fully-automated multiplex fluorescence IHC assay with whole slide multispectral imaging on mouse tissue: phenoptics™ quantitative pathology solutions translational workflow Yi Zheng, PhD; Carla Coltharp, PhD; Ryan Dilworth, PhD; Rachel Schaefer; Linying Liu; Victoria Duckworth; William Kennedy; Darryn Unfricht, PhD; Peter Miller, MS; Milind Rajopadhye, PhD; Biomarkers; Regulatory T cell (Treg cell); Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Tumor stroma
P145Computational assessment of IDO1 feedback modulationJIAN ZHU, PhD; Rebecca L. ZhuBioinformatics; Biomarkers; Immune suppression; MDSC; NK/NK T cell; Regulatory T cell (Treg cell); Systems biology; Tumor infiltrating lymphocytes (TILs)
P146Cell proliferation improves prediction for immune checkpoint inhibitors (ICIs) response in PD-L1 positive TMB high non-small cell lung cancer (NSCLC)Jason Zhu, MD; Matthew K. Labriola, MD; Daniele Marin, MD; Shannon J. McCall, MD; Edwin Yau, MD, PhD; Grace K. Dy; Sarabjot Pabla, MSc, PhD, BS; Sean T. Glenn, PhD; Carl D. Morrison, MD, DVM; Daniel J. George, MD; Tian Zhang, MD; Jeffrey M. Clarke, MDBiomarkers; Checkpoint blockade; Solid tumors; Tumor microenvironment
P147Quantitative assessment of co-expression of PD-L1 and CMTM6 in the tumor microenvironment in non-small cell lung cancer (NSCLC) patients treated with PD-1 pathway blockadeJon Zugazagoitia, MD, PhD; Fahad S. Shabbir, MD; Yuting Liu, PhD candidate; Brian S. Henick, MD; Scott N. Gettinger, MD; Roy S. Herbst, MD, PhD; Kurt A. Schalper, MD, PhD; David L. Rimm, MD, PhD; Biomarkers; Checkpoint blockade; Tumor microenvironment; Tumor stroma
O1Identification and profiling of neoantigen-specific T cells in NSCL cancer patients treated with atezolizumabMichael Fehlings; Suchit Jhunjhunwala, BS, PhD; Marcin Kowanetz, Ph.D.; Bill O'Gorman; Priti S. Hegde, PhD; Jessica Li, Master of Science; Hermi Sumatoh; Boon Heng Lee; Alessandra Nardin, DVM; Leesun Kim; Susan Flynn; Marcus Ballinger, PhD; Evan W. Newell, PhD; Mahesh Yadav, PhD; Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Neoantigens; T cell; Tumor antigens
O2Using artificial intelligence to distinguish subjects with prostate cancer (PCa) from benign prostate hyperplasia (BPH) through immunophenotyping of MDSCs and lymphocyte cell populationsGeorge A. Dominguez, PhD; John Roop; Alex Polo; Anthony J. Campisi, B.S.; Dmitry I. Gabrilovich, MD, PhD; Amit Kumar, PhDBioinformatics; Biomarkers; Clinical study; Granulocyte; Immune monitoring; Myeloid cells; MDSC; Solid tumors
O3Anti-tumor immune responses in metastatic breast cancer exceptional responder patientsAlusha A. Mamchak, PhD; Ngan A. Nguyen, PhD; Danhui Zhang, MD PhD; Felix Chu, MS; Mike Harbell, BS; Beatriz Millare, BS; Kevin S. Williamson; Xiaomu Chen; Xiaobin Tang; Shuwei Jiang; Dongkyoon Kim, BS PhD; Nicole Hasser; Sarah Hippely; Maren K. Levin; Amy Manning-Bog, PhD; Jeff DeFalco; William H. Robinson, MD, PhD; Daniel Emerling, PhD; Norman M. Greenberg, PhD; Guy Cavet, PhD; William H. Robinson, MD, PhD; Joyce O’Shaughnessy, MD; Antibody; B cell; Bioinformatics; Biomarkers; Checkpoint blockade; Chemotherapy; Immune monitoring; Solid tumors; Tumor antigens
O4Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic Stage IV melanomaAdi Diab, MD; Scott Tykodi; Brendan D. Curti, MD; Daniel C. Cho, MD; Michael K. Wong, MD PhD FRCPC; Igor Puzanov, MD, MSCI, FACP; Karl D. Lewis, MD; Michele Maio, MD, PhD; Gregory A. Daniels, MD, PhD; Alexander I. Spira, MD, PhD, FACP; Mary A. Tagliaferri, MD; Alison L. Hannah, MD; Wendy Clemens, PhD; Michael Imperiale; Chantale Bernatchez; Cara Haymaker, PhD; Salah Eddine Bentebibel; Jonathan Zalevsky, PhD; Ute Hoch, PhD; Christie Fanton, PhD; Ahsan N. Rizwan, MPharm, PhD; Sandra Aung, PhD; Fiore Cattaruzza; Ernesto Iaccucci; Dariusz Sawka; Mehmet A. Bilen, MD; Paul Lorigan; Giovanni Grignani; James Larkin, MD; Sekwon Jang, MD; Ewa Kalinka-Warzocha, PhD, MD; Mario Sznol, MD; Michael E. Hurwitz, MD, PhDCheckpoint blockade; Clinical trial; Cytokine; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
O5B-cells and tertiary lymphoid structures (TLS) predict response to immune checkpoint blockade (ICB)Sangeetha M. Reddy, MD, MSci; Beth Helmink, MD PhD; Jianjun Gao, MD PhD; Shaojun Zhang, PhD; Keren Yizhak; Moshe Sade-Feldman; Jorge M. Blando, DVM; Guangchun Han; Vancheswaran Gopalakrishnan, MPH, PhD; Hao Zhao; Wenbin Liu; Hussein A. Tawbi, MD, PhD; Rodabe N. Amaria, MD; Michael Davies, MD, PhD; Patrick Hwu, MD; Jeffrey E. Lee, MD; Jeffrey E. Gershenwald, MD; Scott Woodman; Elizabeth Burton; Lauren E. Haydu, MS, BChe, MIPH; Alexander J. Lazar, MD, PhD; Courtney Hudgens, MS; Alexandria P. Cogdill, MEng; Oscar Krijgsman, PhD; Elisa A. Rozeman, MD; Daniel Peeper, PhD; Christian U. Blank, MD; Ton N. Schumacher, PhD; Emily Keung; Pierre-Olivier Gaudreau; Alexandre Reuben; Christine N. Spencer, PhD; Lisa H. Butterfield, PhD; James P. Allison, PhD; Michael T. Tetzlaff, MD PhD; Florent Petitprez, MS; Wolf Herman Fridman, MD, PhD; Catherine Sautes-Fridman, PhD; Nir Hacohen, PhD; Padmanee Sharma, MD, PhD; Linghua Wang, PhD; Jennifer A. Wargo, MD, MMScB cell; Checkpoint blockade; Gene expression; Immune monitoring; Solid tumors; Tumor microenvironment
O6Comparison of biomarker assay modalities in anti-PD-(L)1 monotherapy: a meta-analysisSteve Lu, B.S.; Ludmila Danilova, PhD; David L. Rimm, MD, PhD; Clifford C. Hoyt, MS; Matthew Hellmann, MD; Janis M. Taube, MD, MSCBiomarkers; Checkpoint blockade; Gene expression; Solid tumors; Tumor microenvironment